Patents Assigned to UNIVERSITÄTSKLINIKUM HEIDELBERG
-
Patent number: 11806251Abstract: Impact instrument for joining prosthetic implants, comprising a housing which accommodates a striker pin, a first spring element associated with the striker pin, a release device and, at least in part, a striking piece, wherein the striking piece projects from the housing at an end face, wherein the release device is movable between a fixing position and a release position, wherein the striker pin is spaced apart from the striking piece the fixing position, wherein the release device moves automatically from the fixing position to the release position when the striking piece moves axially into the housing, in order to release the striker pin once the release position has been reached, so that the latter moves in the direction of the striking piece, accelerated by the first spring element.Type: GrantFiled: October 8, 2019Date of Patent: November 7, 2023Assignees: ENDOCON GMBH, UNIVERSITÄTSKLINIKUM HEIDELBERGInventors: Ulrike Müller, Jan Philippe Kretzer, Klaus Notarbartolo, Robert Lingslebe
-
Patent number: 10155041Abstract: The present invention relates to the field of gastroenterology and, more particular, to the field of intestinal diseases. More specifically, it concerns uses and methods for the treatment of inflammatory bacterial diseases of the intestine. In particular, it relates to diseases that are associated with bacterial invasion of the intestinal mucus, including, inflammatory bowel diseases, and infectious bacterial diseases. Therefore, the present invention provides agents, a pharmaceutical composition and a kit for treating said diseases. It further relates to a use and a method for treating invasive bacterial diseases of the large intestine.Type: GrantFiled: March 25, 2015Date of Patent: December 18, 2018Assignee: Universitaetsklinikum HeidelbergInventor: Wolfgang Stremmel
-
Patent number: 9850308Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.Type: GrantFiled: April 30, 2015Date of Patent: December 26, 2017Assignees: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES OEFFENTLICHEN RECHTS, UNIVERSITAETSKLINIKUM HEIDELBERGInventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
-
Patent number: 9664684Abstract: Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.Type: GrantFiled: April 29, 2011Date of Patent: May 30, 2017Assignees: Deutsches Krebsforschungszentrum, Ruprecht-Karls-Universitaet Heidelberg, Universitaetsklinikum HeidelbergInventors: Nathalia Giese, Jens Werner, Markus Buechler, Thomas Giese, Laurent Daeffler, Celina Czeipluch, Jean Rommelaere, Zahari Raykov
-
Patent number: 9494591Abstract: The present application shows the relationship between variations in the amino acid sequence of histone proteins, more specifically the H3.3 protein, and proliferation-associated disorders. Herewith provided are predictive methods, commercial packages, therapeutic methods and screening methods based on this relationship.Type: GrantFiled: November 21, 2012Date of Patent: November 15, 2016Assignees: THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY, UNIVERSITÄTSKLINIKUM HEIDELBERG, GERMAN CANCER RESEARCH CENTER (DKFZ)Inventors: Nada Jabado, Stefan M. Pfister, Christoph Plass, Andrey Korshunov, Hendrik Witt, Dominik Sturm, David Jones, Peter Lichter, Elke Pfaff
-
Publication number: 20160115236Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.Type: ApplicationFiled: April 30, 2015Publication date: April 28, 2016Applicants: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts, Universitaetsklinikum HeidelbergInventors: Ana MARTIN-VILLALBA, Susanne KLEBER, Benedikt WIESTLER, Peter G. KRAMMER, Christel HEROLD-MENDE, Ignacio SANCHO-MARTINEZ
-
Patent number: 9309320Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.Type: GrantFiled: December 28, 2007Date of Patent: April 12, 2016Assignees: Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts, Universitaetsklinikum HeidelbergInventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez
-
Publication number: 20130101989Abstract: Described is a diagnostic method for predicting the response of a patient to chemovirotherapy or radiovirotherapy, comprising exposing primary tumor cells from a patient, e.g., tumor cells obtained from a brain tumor or pancreatic cancer, to (i) a parvovirus and/or (ii) a chemotherapeutic agent or radiotherapy, and determining the reduction of the expression or concentration of ISG15.Type: ApplicationFiled: April 29, 2011Publication date: April 25, 2013Applicants: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFUNG DES OEFFE, UNIVERSITAETSKLINIKUM HEIDELBERG, RUPRECHT-KARIS-UNIVERSITAET HEIDELBERGInventors: Nathalia Giese, Jens Werner, Markus Buechler, Thomas Giese, Laurent Daeffler, Celina Cziepluch, Jean Rommelaere, Zahari Raykov
-
Publication number: 20100322922Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.Type: ApplicationFiled: December 28, 2007Publication date: December 23, 2010Applicants: Deutsches Krebsforschungszentrum Stiftung des oeffentlichen Rechts, Universitaetsklinikum HeidelbergInventors: Ana Martin-Villalba, Susanne Kleber, Benedikt Wiestler, Peter G. Krammer, Christel Herold-Mende, Ignacio Sancho-Martinez